Literature DB >> 15194082

Malignant ascites: past, present, and future.

Rony A Adam1, Yehuda G Adam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15194082     DOI： 10.1016/j.jamcollsurg.2004.01.035

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN： 1072-7515            Impact factor:   6.113


× No keyword cloud information.
  57 in total

1.  Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.

Authors:  Klaus Pietzner; Ignace Vergote; Armando Santoro; Radoslav Chekerov; Frederik Marmé; Per Rosenberg; Holger Martinius; Hilke Friccius-Quecke; Jalid Sehouli
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

Review 2.  Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.

Authors:  Vathany Kulasingam; Maria P Pavlou; Eleftherios P Diamandis
Journal:  Nat Rev Cancer       Date:  2010-04-12       Impact factor: 60.716

3.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Authors:  Suma L Sangisetty; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2012-04-27

4.  Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites.

Authors:  Myrte Neijenhuis; Tom J G Gevers; Thomas D Atwell; Tim J Gunneson; Amanda C Schimek; Wietske Kievit; Joost P H Drenth; Patrick S Kamath
Journal:  Am J Gastroenterol       Date:  2018-03-20       Impact factor: 10.864

Review 5.  Evaluation and treatment of malignant ascites secondary to gastric cancer.

Authors:  Hiromichi Maeda; Michiya Kobayashi; Junichi Sakamoto
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

6.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

Review 7.  Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Authors:  Filippo Bellati; Chiara Napoletano; Ilary Ruscito; Maria Pastore; Milena Pernice; Morena Antonilli; Marianna Nuti; Pierluigi Benedetti Panici
Journal:  Invest New Drugs       Date:  2009-11-24       Impact factor: 3.850

8.  Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

Authors:  Jalid Sehouli; Klaus Pietzner; Pauline Wimberger; Ignace Vergote; Per Rosenberg; Andreas Schneeweiss; Carsten Bokemeyer; Christoph Salat; Giovanni Scambia; Dominique Berton-Rigaud; Armando Santoro; Andrés Cervantes; Olivier Trédan; Christophe Tournigand; Nicoletta Colombo; Alexander S Dudnichenko; Anneke Westermann; Hilke Friccius-Quecke; Florian Lordick
Journal:  Med Oncol       Date:  2014-06-26       Impact factor: 3.064

9.  Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Authors:  Cynthia Kuk; Vathany Kulasingam; C Geeth Gunawardana; Chris R Smith; Ihor Batruch; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2008-12-01       Impact factor: 5.911

Review 10.  Management of ascites.

Authors:  Fedja A Rochling; Rowen K Zetterman
Journal:  Drugs       Date:  2009       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.